Agilent and the University of Queensland Centre for Clinical Research in Brisbane, Australia are collaborating on a study to increase understanding of the genomic differences between young and older patients with oral cancer and between progressive and non-progressive oral potentially malignant lesions.
Oral cancer, one of a group of head and neck cancers, is the sixth most common cancer worldwide. Over 275,000 new cases are diagnosed per year, resulting in nearly 125,000 deaths annually, according to the National Center for Biotechnology Information, under the U.S. National Institutes of Health.
Researchers at the UQ Centre for Clinical Research will use Agilent’s SureSelect target enrichment system to enable greater understanding of the genetic changes that characterize oral cancers.
For more information go to: